Team 5: Atherothrombotic Disease in Heart and Brain

Group leader: Gabriel STEG

ClinicalresearchTeam 5 “Translational research on cardio- and cerebrovascular disease” started with an innovative collaboration of cardiologists and neurologists (formerly within the “clinical research on atherothrombosis” team) implemented by basic science researchers, coming from the former team on “Vascular Remodelling”. Our projects are focussed on 1/ international clinical trials assessing medical strategies and new therapies in coronary artery disease and cerebrovascular disease, particularly acute coronary syndromes and stroke, and 2/ on translational research aiming to uncover new biological markers of atherothrombosis in humans as a basis for new diagnostic/theranostic tools, but also for developing new therapeutic tools (in particular HDL-based therapies).

There is a dire need for therapies to help address the cardiovascular consequences of the diabetes and obesity epidemic. While important, this is not limited to the development of more potent and safer agents to prevent thrombosis, stabilize or prevent atherosclerosis, or treat hyperglycemia. The potential hazards (on cardiovascular mortality) of aggressive management of hyperglycemia have emphasized the need to fully assess the cardiovascular impact of antidiabetic drugs. Recent clinical trials also underlined the importance of rigorous evaluation of the clinical effectiveness of routine therapeutic strategies. Future treatments will need to demonstrate safety and cost-effectiveness in addition to efficacy. Our aim is to focus on new, effective, safe, affordable and easily implementable therapeutic strategies for atherothrombosis and diabetes.

Name
Position
Phone
Email
AMARENCO PierrePU-PH01.40.25.87.25pierre.amarenco@aphp.fr
AMGOUD YasmineDoctorant yas-a@live.com
BACHER AnneARC
BENTARFAYA IkramMaster 2
BOUFFARD CatherineInfirmiere catherine.bouffard@aphp.fr
CHOQUEUX ChristineIE01.40.25.86.12christine.choqueux@inserm.fr
CODOGNO IsabelleARC isabelle.codogno@gmail.com
CUNGH Hong AnhAHU
DUCROCQ GregoryDoctorant gregory.ducrocq@aphp.fr
FABRE Jean-EtienneDR01.40.25.86.07jean-etienne.fabre@inserm.fr
FARNOUD RezaARC01.57.27.53.52reza.farnoud@aphp.fr
JULIARD Jean-Michel 01.40.25.85.21jean-michel.juliard@ap-ho-paris.fr
KLEIN IsabellePH01.40.25.82.45isabelle.klein@aphp.fr
LAVALLEE PhilippaMCUPH01.40.25.70.33philippalavallee@yahoo.fr
LESECHE Guy PU-PH guy.leseche@aphp.fr
LONGROIS DanPU-PH01.40.25.74.27dan.longrois@aphp.fr
LOUEDEC LilianeAI01.40.25.86.14liliane.louedec@inserm.fr
MANI SalmaDoctorant
MAWHIN Marie-AnneDoctorant01.40.25.86.06marie-anne.mawhin@inserm.fr
MUHAMMAD ABDELMONEIM HebaDoctorant
NOREL Xavier IE01.40.25.75.29xnorel@hotmail.com
OUGHIRI MeryemARC meryem_11@hotmail.fr
SIMON TobassomePU-PH tabassome.simon@aphp.fr
SONNEVILLE RomainPH01.40.25.61.39romain.sonneville@aphp.fr
SPIELER Jean-FrançoisECO01.40.25.87.28jean-francois.spieler@aphp.fr
STEG Philippe GabrielPU-PH01.40.25.73.25gabriel.steg@aphp.fr
TCHITCHINADZE Maria 01.40.25.68.14maria.tchitchinadze@aphp.fr
TOUBOUL Pierre-JeanPATT01.40.25.87.25pjtw@noos.fr
YUNG Sonia Master 2
ZIRKA GaiaMaster 2 gaiazirka@gmail.com

2017

1.
Abboud H, Sissani L, Labreuche J, Arauz A, Bousser MG, Bryer A, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Lavados PM, Massaro A, Mattle HP, Munoz Collazos M, Rothwell PM, Steg PG, Vicaut E, Yamouth B, Amarenco P. 2017. Specificities of Ischemic Stroke Risk Factors in Arab-Speaking Countries. Cerebrovasc Dis 43:169–177.
1.
Abell JE, Laing SM, Barker TC, Norry EC, Starzyk K, Goodman SG, Dellborg M, Steg PG, Giugliano RP. 2017. Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. Eur Heart J Cardiovasc Pharmacother.
1.
Abnousi F, Sundaram V, Yong CM, Prats J, Deliargyris EN, Stone GW, Hamm CW, Steg PG, Gibson CM, White HD, Price MJ, Généreux P, Desai M, Yang L, Ding VY, Harrington RA, Bhatt DL, Mahaffey KW. 2017. Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J 188:147–155.
1.
Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Reid CM, Baumgartner I, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G. 2017. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol.
1.
Amarenco P, Sissani L, Labreuche J, Vicaut E, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle H, Rothwell PM, Steg PG, Diener HC, Sacco RL, Greving JP, Algra A. 2017. The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment. Cerebrovasc Dis 43:145–151.
1.
Bavry AA, Elgendy IY, Elbez Y, Mahmoud AN, Sorbets E, Steg PG, Bhatt DL. 2017. Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. Clin Cardiol.
1.
Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM. 2017. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol 40:138–148.
1.
Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, Funck-Brentano C, Girard PM, Costagliola D, Cohen A, Guiguet M. 2017. Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. Am Heart J 183:91–101.
1.
Chandrasekhar J, Baber U, Sartori S, Aquino M, Tomey M, Kruckoff M, Moliterno D, Henry TD, Weisz G, Gibson CM, Iakovou I, Kini A, Faggioni M, Vogel B, Farhan S, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen D, Stuckey T, Ariti C, Pocock S, Dangas G, Mehran R. 2017. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. Int J Cardiol.
1.
Chandrasekhar J, Bansilal S, Baber U, Sartori S, Aquino M, Farhan S, Vogel B, Faggioni M, Giustino G, Ariti C, Colombo A, Chieffo A, Kini A, Saporito R, Michael Gibson C, Witzenbichler B, Cohen D, Moliterno D, Stuckey T, Henry T, Pocock S, Dangas G, Gabriel Steg P, Mehran R. 2017. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv 89:E217–E225.
1.
Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M. 2017. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025–1034.
1.
Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. 2017. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol 2:525–534.
1.
Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Cannon CP, Becker RC, James SK, Katus HA, Lopes RD, Sorbets E, Wallentin L, Steg PG. 2017. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. Am Heart J 186:91–99.
1.
Fabris E, Kilic S, Van’t Hof AW, Ten Berg J, Ayesta A, Zeymer U, Hamon M, Soulat L, Bernstein D, Anthopoulos P, Deliargyris EN, Steg PG. 2017. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. JAMA Cardiol.
1.
Faggioni M, Baber U, Sartori S, Giustino G, Cohen DJ, Henry TD, Farhan S, Ariti C, Dangas G, Gibson M, Giacoppo D, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. 2017. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv 10:645–654.
1.
Fanaroff AC, Hasselblad V, Roe MT, Bhatt DL, James SK, Steg PG, Gibson CM, Ohman EM. 2017. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Int J Cardiol.
1.
Feldman L, Steg PG, Amsallem M, Puymirat E, Sorbets E, Elbaz M, Ritz B, Hueber A, Cattan S, Piot C, Ferrières J, Simon T, Danchin N. 2017. Editor’s Choice-Medically managed patients with non-ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease. Eur Heart J Acute Cardiovasc Care 6:262–271.
1.
Hagström E, Held C, Stewart RA, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L. 2017. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clin Chem 63:325–333.
1.
Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet JP, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheugt FWA, Lanas A, Al-Shahi Salman R, Steg PG, Huber K. 2017. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 38:1455–1462.
1.
Hobeanu C, Lavallée PC, Rothwell PM, Sissani L, Albers GW, Bornstein NM, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Labreuche J, Molina C, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wong LK, Amarenco P. 2017. Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting. Stroke 48:1005–1010.
1.
Hoshino T, Uchiyama S, Wong LKS, Sissani L, Albers GW, Bornstein NM, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Labreuche J, Lavallée PC, Molina C, Rothwell PM, Steg PG, Touboul PJ, Vicaut É, Amarenco P. 2017. Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org. Stroke.
1.
Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif JC, Tendera M, Reid CM, Danchin N, Stepinska J, Steg PG, Fox KM. 2017. Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease. Am J Med 130:720–730.
1.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. 2017. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med 376:1933–1942.
1.
Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. 2017. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc 6.
1.
Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L. 2017. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem 63:573–584.
1.
Lowenstern A, Storey RF, Neely M, Sun JL, Angiolillo DJ, Cannon CP, Himmelmann A, Huber K, James SK, Katus HA, Morais J, Siegbahn A, Steg PG, Wallentin L, Becker RC. 2017. Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. J Thromb Thrombolysis.
1.
Manzo-Silberman S, Nicaise-Roland P, Neukirch C, Tubach F, Huisse MG, Chollet-Martin S, Abergel H, Driss F, Alfaiate T, Ajzenberg N, Steg PG. 2017. Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. Eur Heart J Cardiovasc Pharmacother 3:77–81.
1.
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park DW, Bode C, Welsh RC, Gibson CM. 2017. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 389:1799–1808.
1.
Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Ahn JM, Park SJ, Schüpke S, Kastrati A, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. 2017. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. J Am Coll Cardiol 69:2011–2022.
1.
Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Gibson CM, White HD, Storey RF. 2017. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb Haemost 117:1093–1100.
1.
Parma Z, Steg PG, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif JC, Morais J, Gamba MA, Kääb S, Tendera For The Clarify Investigators M. 2017. Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry. Pol Arch Med Wewn 127:107–114.
1.
Philippe F, Blin P, Bouée S, Laurendeau C, Torreton E, Gourmelin J, Velkovski-Rouyer M, Levy-Bachelot L, Steg G. 2017. [Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)]. Ann Cardiol Angeiol (Paris) 66:74–80.
1.
Pollack CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CP. 2017. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol.
1.
Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG. 2017. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart.
1.
Puymirat E, Caudron J, Steg PG, Lemesle G, Cottin Y, Coste P, Schiele F, de Labriolle A, Bataille V, Ferrières J, Simon T, Danchin N. 2017. Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. Eur Heart J Acute Cardiovasc Care 6:26–33.
1.
Rakowski T, Dudek D, van ’t Hof A, Ten Berg J, Soulat L, Zeymer U, Lapostolle F, Anthopoulos P, Bernstein D, Deliargyris EN, Steg PG. 2017. Impact of acute infarct-related artery patency before percutaneous coronary intervention on 30-day outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention in the EUROMAX trial. Eur Heart J Acute Cardiovasc Care 2048872617690888.
1.
Roguin A, Camenzind E, Kerner A, Beyar R, Boersma E, Mauri L, Steg PG, Wijns W. 2017. Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial. JACC Cardiovasc Interv 10:548–556.
1.
Roussel R, Steg PG, Mohammedi K, Marre M, Potier L. 2017. Prevention of Cardiovascular Disease by the Reduction of Glycemic Exposure in Type 2 Diabetes: A Perspective on Glucose-Lowering Interventions. Diabetes Obes Metab.
1.
Sawlani NN, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. 2017. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv 10.
1.
Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D’Agostino RB, Massaro JM, Mauri L. 2017. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol 2:478–487.
1.
Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L. 2017. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv 10:942–954.
1.
Sorbets E, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG. 2017. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. Clin Cardiol.
1.
Steg PG, Bhatt DL. 2017. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care 6:93–97.
1.
Steg PG, Simon T. 2017. Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials? Eur Heart J 38:1044–1047.
1.
Tan NS, Sarak B, Fox KA, Brieger D, Steg PG, Gale CP, Bhatt DL, Spencer FA, Grondin FR, Goodman SG, Yan AT. 2017. Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. Eur Heart J Acute Cardiovasc Care 2048872617700871.
1.
Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. 2017. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost 117:940–947.
1.
Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL. 2017. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol 69:176–185.
1.
Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL. 2017. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol 2:127–135.
1.
Varshney A, Steg PG, Elbez Y, Sorbets E, Eagle KA, Bhatt DL. 2017. Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis. Int J Cardiol.
1.
Vidal-Petiot E, Bhatt DL, Fox KM, Steg PG. 2017. Blood pressure and cardiovascular outcomes: a closer look - Authors’ reply. Lancet 389:1296–1297.
1.
Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, Wallentin L, White HD, Steg PG. 2017. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. Eur Heart J.
1.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. 2017. Corrigendum to “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease” [Am Heart J 181 (2016) 92-100]. Am Heart J 184:156.
1.
Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, Thomas L, Wojdyla DM, Hanna M, Keltai M, Steg PG, De Caterina R, Wallentin L, van Gilst WH. 2017. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 185:140–149.
1.
van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FL. 2017. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. Eur Heart J.

2016

1.
Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G. 2016. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. Clin Cardiol 39:670–677.
1.
Abtan J, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Abnousi F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL. 2016. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC Cardiovasc Interv 9:1905–13.
1.
Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wong LK. 2016. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. N Engl J Med 374:1533–42.
1.
Arangalage D, Lepage L, Faille D, Cimadevilla C, Dilly MP, Papy E, Alhenc-Gelas M, Ghodbane W, Nataf P, Iung B, Steg PG, Vahanian A, Ajzenberg N, Messika-Zeitoun D. 2016. Presentation, management and outcome of heparin-induced thrombocytopenia after valvular heart surgery. Eur J Cardiothorac Surg 50:1132–1138.
1.
Arbel Y, FitzGerald G, Yan AT, Tan MK, Fox KA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Budaj A, Lopez-Sendon J, Avezum A, Granger CB, Goodman SG. 2016. Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. Int J Cardiol 218:291–7.
1.
Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Weisz G, Colombo A, Pocock S, Mehran R. 2016. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv 9:1349–57.
1.
Baber U, Dangas G, Cohen DJ, Gibson CM, Mehta SR, Angiolillo DJ, Pocock SJ, Krucoff MW, Kastrati A, Ohman EM, Steg PG, Badimon J, Zafar MU, Chandrasekhar J, Sartori S, Aquino M, Mehran R. 2016. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J 182:125–134.
1.
Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG, Windecker S, Leon MB, Wijns W, Serruys PW, Valgimigli M, Stone GW, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. 2016. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv 9:28–38.
1.
Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. 2016. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol 67:2224–34.
1.
Bailleul C, Puymirat E, Aissaoui N, Schiele F, Ducrocq G, Coste P, Blanchard D, Brasselet C, Elbaz M, Steg PG, Le Breton H, Bonnefoy-Cudraz E, Montalescot G, Cottin Y, Goldstein P, Ferrières J, Simon T, Danchin N. 2016. Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry). Am J Cardiol 117:17–21.
1.
Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG. 2016. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol 67:2732–40.
1.
Blin P, Philippe F, Bouée S, Laurendeau C, Torreton E, Gourmelin J, Leproust S, Levy-Bachelot L, Steg PG. 2016. Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis. Int J Cardiol 219:387–93.
1.
Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Špinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS. 2016. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol 1:425–32.
1.
Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, López-Sendón J, Diaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS. 2016. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 37:1133–42.
1.
Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MT, Jensen EC, Held P, Braunwald E, Sabatine MS. 2016. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol 67:2719–28.
1.
Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Špinar J, Seung KB, Hu D, Dalby AJ, Jensen E, Held P, Morrow DA, Braunwald E, Sabatine MS. 2016. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation 134:861–71.
1.
Bouleti C, Baudry G, Iung B, Arangalage D, Abtan J, Ducrocq G, Steg PG, Vahanian A, Henry-Feugeas MC, Pasi N, Chillon S, Pitocco F, Laissy JP, Ou P. 2016. Usefulness of Late Iodine Enhancement on Spectral CT in Acute Myocarditis. JACC Cardiovasc Imaging.
1.
Brochet É, Ducrocq G, Extramiana F, Feldman L, Himbert D, Iung B, Jondeau G, Juliard JM, Steg G, Vahanian A. 2016. [What’s new in cardiology]. Rev Prat 66:633–40.
1.
Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, Im K, James SK, Michelson EL, Himmelmann A, Held C, Varenhorst C, Wallentin L, Scirica BM. 2016. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Arrhythm Electrophysiol 9:e002951.
1.
Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH. 2016. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol 39:555–564.
1.
Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA. 2016. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation 134:723–33.
1.
Cavender MA, Scirica BM, Raz I, Steg PG, McGuire DK, Leiter LA, Hirshberg B, Davidson J, Cahn A, Mosenzon O, Im K, Braunwald E, Bhatt DL. 2016. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. Am J Med 129:340.e1–8.
1.
Chiang CE, Naditch-Brûlé L, Brette S, Silva-Cardoso J, Gamra H, Murin J, Zharinov OJ, Steg PG. 2016. Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey. PLoS ONE 11:e0147536.
1.
Chopra H, Arangalage D, Bouleti C, Zarka S, Fayard F, Chillon S, Laissy JP, Henry-Feugeas MC, Steg PG, Vahanian A, Ou P. 2016. Prognostic value of the infarct- and non-infarct like patterns and cardiovascular magnetic resonance parameters on long-term outcome of patients after acute myocarditis. Int J Cardiol 212:63–9.
1.
Dangas GD, Schoos MM, Steg PG, Mehran R, Clemmensen P, van ’t Hof A, Prats J, Bernstein D, Deliargyris EN, Stone GW. 2016. Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials. Circ Cardiovasc Interv 9:e003272.
1.
Ducrocq G, Steg PG, Van’t Hof A, Zeymer U, Mehran R, Hamm CW, Bernstein D, Prats J, Deliargyris EN, Stone GW. 2016. Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. Eur Heart J Acute Cardiovasc Care.
1.
Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica BM. 2016. Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Am Heart Assoc 5.
1.
Giannitsis E, Wallentin L, James SK, Bertilsson M, Siegbahn A, Storey RF, Husted S, Cannon CP, Armstrong PW, Steg PG, Katus HA. 2016. Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. Eur Heart J Acute Cardiovasc Care.
1.
Gibson CM, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D’Andrea D, Merkely B, Zarebinski M, Ophius TO, Harrington RA. 2016. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. Am Heart J 180:22–8.
1.
Giustino G, Baber U, Aquino M, Sartori S, Stone GW, Leon MB, Genereux P, Dangas GD, Chandrasekhar J, Kimura T, Salianski O, Stefanini GG, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Saporito R, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. 2016. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv 9:674–84.
1.
Giustino G, Baber U, Salianski O, Sartori S, Stone GW, Leon MB, Aquino M, Stefanini GG, Steg PG, Windecker S, O’ Donoghue M, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Dangas GD, Cha JY, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Genereux P, Chieffo A, Mehran R. 2016. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv 9:e002995.
1.
Giustino G, Mastoris I, Baber U, Sartori S, Stone GW, Leon MB, Serruys PW, Kastrati A, Windecker S, Valgimigli M, Dangas GD, Von Birgelen C, Smits PC, Kandzari D, Galatius S, Wijns W, Steg PG, Stefanini GG, Aquino M, Morice MC, Camenzind E, Weisz G, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Chieffo A, Mehran R. 2016. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv 9:1890–901.
1.
Gonzalez-Valcarcel J, Sissani L, Labreuche J, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Steg PG, Vicaut E, Amarenco P. 2016. Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. Stroke 47:1045–52.
1.
Grodzinsky A, Arnold SV, Wang TY, Sharma P, Gosch K, Jones PG, Bhatt DL, Steg PG, McGuire DK, Cohen DJ, Spertus JA, Chhatriwalla AK, Lind M, Graham G, Kosiborod M. 2016. Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. Am Heart J 182:111–118.
1.
Gutierrez JA, Harrington RA, Blankenship JC, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Généreux P, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. 2016. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J 37:1122–30.
1.
Hagström E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A, Wallentin L. 2016. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J 37:1325–33.
1.
Hajage D, Tubach F, Steg PG, Bhatt DL, De Rycke Y. 2016. On the use of propensity scores in case of rare exposure. BMC Med Res Methodol 16:38.
1.
Helft G, Steg PG, Le Feuvre C, Georges JL, Carrie D, Dreyfus X, Furber A, Leclercq F, Eltchaninoff H, Falquier JF, Henry P, Cattan S, Sebagh L, Michel PL, Tuambilangana A, Hammoudi N, Boccara F, Cayla G, Douard H, Diallo A, Berman E, Komajda M, Metzger JP, Vicaut E. 2016. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 37:365–74.
1.
Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L. 2016. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv 9:138–47.
1.
Jatene T, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. 2016. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. J Am Coll Cardiol 67:596–8.
1.
Johansson Å, Eriksson N, Lindholm D, Varenhorst C, James S, Syvänen AC, Axelsson T, Siegbahn A, Barratt BJ, Becker RC, Himmelmann A, Katus HA, Steg PG, Storey RF, Wallentin L. 2016. Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet 25:1447–56.
1.
Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, Kedev S, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemela K, Bernat I, Cantor WJ, Cheema AN, Steg PG, Welsh RC, Sheth T, Bertrand OF, Avezum A, Bhindi R, Natarajan MK, Horak D, Leung RC, Kassam S, Rao SV, El-Omar M, Mehta SR, Velianou JL, Pancholy S, Džavík V. 2016. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet 387:127–35.
1.
Juliard JM, Golmard JL, Feldman LJ, Himbert D, Nejjari M, Ducrocq G, Sorbets E, Garbarz E, Aubry P, Duchatelle V, Vahanian A, Steg PG. 2016. Impact of participation in randomized trials of reperfusion therapy on the time to reperfusion and hospital mortality in ST-segment elevation myocardial infarction: A single-centre cohort study. Eur Heart J Acute Cardiovasc Care 5:193–7.
1.
Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L. 2016. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol 67:2492–502.
1.
Kilic S, Van’t Hof AW, Ten Berg J, Lopez AA, Zeymer U, Hamon M, Soulat L, Bernstein D, Deliargyris EN, Steg PG. 2016. Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial. Int J Cardiol 211:119–23.
1.
Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR. 2016. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost 116:544–53.
1.
Komajda M, Weidinger F, Kerneis M, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Steg PG, Tavazzi L, Valgimigli M, Szwed H, Majda W, Olivari Z, Van Belle E, Shlyakhto EV, Mintale I, Slapikas R, Rittger H, Mendes M, Tsioufis C, Balanescu S, Laroche C, Maggioni AP. 2016. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). Eur Heart J 37:152–60.
1.
Leonardi S, Lopes RD, Steg PG, Abnousi F, Menozzi A, Prats J, Mangum S, Wilson M, Todd M, Stone GW, Gibson CM, Hamm CW, Price MJ, White HD, Harrington RA, Bhatt DL, Mahaffey KW. 2016. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care.
1.
Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH. 2016. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet 387:349–56.
1.
Magnani G, Storey RF, Steg G, Bhatt DL, Cohen M, Kuder J, Im K, Aylward P, Ardissino D, Isaza D, Parkhomenko A, Goudev AR, Dellborg M, Kontny F, Corbalan R, Medina F, Jensen EC, Held P, Braunwald E, Sabatine MS, Bonaca MP. 2016. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J 37:400–8.
1.
Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D’Agostino RB, Braunwald E, Kereiakes DJ. 2016. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 37:378–85.
1.
Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L. 2016. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation 133:1772–82.
1.
Michael Gibson C, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D’Andrea DM, Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA. 2016. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation 134:1918–1930.
1.
Narasimhan C, Verma JS, Ravi Kishore AG, Singh B, Dani S, Chawala K, Haque A, Khan A, Nair M, Vora A, Rajasekhar V, Thomas JM, Gupta A, Naik A, Prakash VS, Naditch L, Gabriel Steg P. 2016. Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. Indian Heart J 68:663–670.
1.
O’Donoghue ML, Bhatt DL, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA. 2016. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. Circulation 133:248–55.
1.
O’Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA. 2016. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA 315:1591–9.
1.
Patel MR, Armstrong PW, Bhatt DL, Braunwald E, Camm AJ, Fox KA, Harrington RA, Hiatt WR, James SK, Kirtane AJ, Leon MB, Lincoff AM, Mahaffey KW, Mauri L, Mehran R, Mehta SR, Montalescot G, Nicholls SJ, Perkovic V, Peterson ED, Pocock SJ, Roe MT, Sabatine MS, Sekeres M, Solomon SD, Steg G, Stone GW, Van de Werf F, Wallentin L, White HD, Gibson M. 2016. Sharing Data from Cardiovascular Clinical Trials–A Proposal. N Engl J Med 375:407–9.
1.
Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM. 2016. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Assoc 5:e002197.
1.
Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, Alexander JH, Adkinson NF, Levinson AI. 2016. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol 138:1712–1715.
1.
Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh R, Bode C, Gibson CM. 2016. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. Am Heart J 174:120–8.
1.
Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, Cayla G, Cattan S, Steg G, Mock L, Ducrocq G, Goldstein P, Schiele F, Bonnefoy-Cudraz E, Simon T, Danchin N. 2016. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J 37:1063–71.
1.
Puymirat E, Riant E, Aissoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrières J, Juillière Y, Simon T, Danchin N. 2016. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ 354:i4801.
1.
Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. 2016. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost 115:1240–8.
1.
Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L. 2016. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation 134:989–998.
1.
Riegger J, Byrne RA, Joner M, Chandraratne S, Gershlick AH, Ten Berg JM, Adriaenssens T, Guagliumi G, Godschalk TC, Neumann FJ, Trenk D, Feldman LJ, Steg PG, Desmet W, Alfonso F, Goodall AH, Wojdyla R, Dudek D, Philippi V, Opinaldo S, Titova A, Malik N, Cotton J, Jhagroe DA, Heestermans AA, Sinnaeve P, Vermeersch P, Valina C, Schulz C, Kastrati A, Massberg S. 2016. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. Eur Heart J 37:1538–49.
1.
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol Ç, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J. 2016. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315.
1.
Sarak B, Goodman SG, Yan RT, Tan MK, Steg PG, Tan NS, Fox KA, Udell JA, Brieger D, Welsh RC, Gale CP, Yan AT. 2016. Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart 102:1396–402.
1.
Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, Mosenzon O, Udell JA, Hirshberg B, Pollack PS, Steg PG, Jarolim P, Morrow DA. 2016. Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 1:989–998.
1.
Selvaraj S, Bhatt DL, Stone GW, Gibson CM, Steg PG, Hamm CW, Price MJ, Deliargyris EN, Prats J, Mahaffey KW, White HD, Harrington RA. 2016. “Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. J Am Coll Cardiol 68:2385–2387.
1.
Selvaraj S, Steg PG, Elbez Y, Sorbets E, Feldman LJ, Eagle KA, Ohman EM, Blacher J, Bhatt DL. 2016. Reply: Pulse Pressure and Cardiovascular Death. J Am Coll Cardiol 68:132–3.
1.
Selvaraj S, Steg PG, Elbez Y, Sorbets E, Feldman LJ, Eagle KA, Ohman EM, Blacher J, Bhatt DL. 2016. Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry. J Am Coll Cardiol 67:392–403.
1.
Selvaraj S, Steg PG, Elbez Y, Sorbets E, Feldman LJ, Eagle KA, Ohman EM, Blacher J, Bhatt DL. 2016. Reply: Mean Arterial Pressure Estimation by a Non-Traditional Formula and Fractional Pulse Pressure. J Am Coll Cardiol 68:669.
1.
Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, Steg PG, Van de Werf F, Armstrong PW. 2016. Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. J Am Heart Assoc 5.
1.
Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, Lopes RD, Steg PG, Storey RF, Wallentin L, Cannon CP. 2016. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J 177:1–8.
1.
Steg PG, Ducrocq G. 2016. Future of the Prevention and Treatment of Coronary Artery Disease. Circ J 80:1067–72.
1.
Steg PG, Roussel R. 2016. Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort? Circulation 134:571–3.
1.
Steg PG, Serruys PW, Abdelghani M, Wijns W. 2016. The year in cardiology 2015: coronary intervention. Eur Heart J 37:335–43.
1.
Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP. 2016. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med 375:2223–2235.
1.
Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MS. 2016. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol 67:1145–54.
1.
Ten Haaf M, Appelman Y, Wijns W, Steg G, Mauri L, Rademaker-Havinga T, Wetzels G, Bousquette L, Camenzind E, Boersma E. 2016. Frequency of Stent Thrombosis Risk at 5 Years in Women Versus Men With Zotarolimus-Eluting Compared With Sirolimus-Eluting Stent. Am J Cardiol 118:1178–1186.
1.
Tendera M, Chassany O, Ferrari R, Ford I, Steg PG, Tardif JC, Fox K. 2016. Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy. Circ Cardiovasc Qual Outcomes 9:31–8.
1.
Vaduganathan M, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. 2016. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv 9.
1.
Velders MA, Abtan J, Angiolillo DJ, Ardissino D, Harrington RA, Hellkamp A, Himmelmann A, Husted S, Katus HA, Meier B, Schulte PJ, Storey RF, Wallentin L, Gabriel Steg P, James SK. 2016. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 102:617–25.
1.
Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PG. 2016. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 388:2142–2152.
1.
Vranckx P, Valgimigli M, Windecker S, Steg PG, Hamm C, Jüni P, Garcia-Garcia HM, van Es GA, Serruys PW. 2016. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention 12:1239–1245.
1.
Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Östlund O, White HD. 2016. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc 5.
1.
Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW. 2016. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 387:136–45.
1.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. 2016. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. Am Heart J 181:92–100.
1.
Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L. 2016. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 315:1735–49.
1.
Yu J, Baber U, Mastoris I, Dangas G, Sartori S, Steg PG, Cohen DJ, Giustino G, Chandrasekhar J, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Colombo A, Pocock S, Mehran R. 2016. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv 9:1461–9.
1.
Zeller M, Labalette-Bart M, Juliard JM, Potier L, Feldman LJ, Steg PG, Cottin Y, Roussel R. 2016. Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. Int J Cardiol 220:137–42.
1.
Zhang H, Goodman SG, Yan RT, Steg PG, Kornder JM, Gyenes GT, Grondin FR, Brieger D, DeYoung JP, Gallo R, Yan AT. 2016. In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. Eur Heart J Acute Cardiovasc Care 5:214–22.

2015

1.
Alexopoulos D, Bhatt DL, Hamm CW, Steg PG, Stone GW. 2015. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap. Am Heart J 170:3–12.
1.
Alnasser SM, Huang W, Gore JM, Steg PG, Eagle KA, Anderson FA, Fox KA, Gurfinkel E, Brieger D, Klein W, van de Werf F, Avezum Á, Montalescot G, Gulba DC, Budaj A, Lopez-Sendon J, Granger CB, Kennelly BM, Goldberg RJ, Fleming E, Goodman SG. 2015. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. Am J Med 128:766–75.
1.
Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D. 2015. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. J Am Heart Assoc 4:e002490.
1.
Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. 2015. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis 40:317–22.
1.
Blin P, Philippe F, Laurendeau C, Bouee S, Gourmelen J, Levy Bachelot L, Leproust S, Steg PG. 2015. Increased Costs Due To Myocardial Infarction (Mi) In France: An Observational Analysis Using A Claims Database. Value Health 18:A386.
1.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS. 2015. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–800.
1.
Bouleti C, Mathivet T, Serfaty JM, Vignolles N, Berland E, Monnot C, Cluzel P, Steg PG, Montalescot G, Germain S. 2015. Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow. Int J Cardiol 187:511–6.
1.
Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL. 2015. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 132:923–31.
1.
Clemmensen P, Wiberg S, Van’t Hof A, Deliargyris EN, Coste P, Ten Berg J, Cavallini C, Hamon M, Dudek D, Zeymer U, Tabone X, Kristensen SD, Bernstein D, Anthopoulos P, Prats J, Steg PG. 2015. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography). JACC Cardiovasc Interv 8:214–20.
1.
Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guérin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit JF, Jouve B, Motreff P, Tron C, Labeque JN, Steg PG, Cottin Y, Range G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, De Poli F, Morice MC, Ider O, Dubois-Randé JL, Unterseeh T, Le Breton H, Béard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I, Jossan C, Derumeaux G, Mewton N, Ovize M. 2015. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med 373:1021–31.
1.
Degrell P, Sorbets E, Feldman LJ, Steg PG, Ducrocq G. 2015. Screening for coronary artery disease in asymptomatic individuals: Why and how? Arch Cardiovasc Dis 108:675–82.
1.
Donataccio MP, Puymirat E, Parapid B, Steg PG, Eltchaninoff H, Weber S, Ferrari E, Vilarem D, Charpentier S, Manzo-Silberman S, Ferrières J, Danchin N, Simon T. 2015. In-hospital outcomes and long-term mortality according to sex and management strategy in acute myocardial infarction. Insights from the French ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2005 Registry. Int J Cardiol 201:265–70.
1.
Ducrocq G, Jolly S, Mehta SR, Rao SV, Patel T, Moreno R, Gao P, Steg PG. 2015. Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial. Circ Cardiovasc Interv 8.
1.
Ducrocq G, Puymirat E, Steg PG, Henry P, Martelet M, Karam C, Schiele F, Simon T, Danchin N. 2015. Blood transfusion, bleeding, anemia, and survival in patients with acute myocardial infarction: FAST-MI registry. Am Heart J 170:726–734.e2.
1.
Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, Lassila R, Storey RF, Sorbets E, Wallentin L, Steg PG. 2015. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention 11:737–45.
1.
Ducrocq G, Steg PG. 2015. Treating coronary artery disease in patients with a history of cerebrovascular disease. Arch Cardiovasc Dis 108:606–11.
1.
Elmariah S, Mauri L, Doros G, Galper BZ, O’Neill KE, Steg PG, Kereiakes DJ, Yeh RW. 2015. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 385:792–8.
1.
Erglis A, Mintale I, Latkovskis G, Balode I, Jegere S, Bajare I, Rozenbergs A, Greenlaw N, Ferrari R, Steg PG. 2015. Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry. Medicina (Kaunas) 51:240–6.
1.
Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG. 2015. Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PLoS ONE 10:e0125164.
1.
Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox K, Hu D, Shalnova S, Steg PG. 2015. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. Eur J Prev Cardiol 22:1056–65.
1.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. 2015. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J 36:3291–6.
1.
Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG. 2015. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart 101:692–8.
1.
Giustino G, Baber U, Stefanini GG, Aquino M, Stone GW, Sartori S, Steg PG, Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice MC, Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C, Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. 2015. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol 116:845–52.
1.
Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S. 2015. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings. J Thromb Haemost 13:1597–605.
1.
Halcox JP, Tubach F, Sazova O, Sweet S, Medina J. 2015. Reclassification of European patients’ cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm. Eur J Prev Cardiol 22:200–2.
1.
Hamill V, Ford I, Fox K, Böhm M, Borer JS, Ferrari R, Komajda M, Steg PG, Tavazzi L, Tendera M, Swedberg K. 2015. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. Am J Med 128:1102–1108.e6.
1.
Hamon M, Coste P, Van’t Hof A, Ten Berg J, Clemmensen P, Tabone X, Benamer H, Kristensen SD, Cavallini C, Marzocchi A, Hamm C, Kanic V, Bernstein D, Anthopoulos P, Deliargyris EN, Steg PG. 2015. Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial. Circ Cardiovasc Interv 8:e002049.
1.
Hansel B, Roussel R, Elbez Y, Marre M, Krempf M, Ikeda Y, Eagle KA, Elisaf M, Bhatt DL, Steg PG. 2015. Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. Eur Heart J 36:2716–28.
1.
Johansson Å, Eriksson N, Becker RC, Storey RF, Himmelmann A, Hagström E, Varenhorst C, Axelsson T, Barratt BJ, James SK, Katus HA, Steg PG, Syvänen AC, Wallentin L, Siegbahn A. 2015. NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circ Cardiovasc Genet 8:498–506.
1.
Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemelä K, Steg PG, Bernat I, Xu Y, Cantor WJ, Overgaard CB, Naber CK, Cheema AN, Welsh RC, Bertrand OF, Avezum A, Bhindi R, Pancholy S, Rao SV, Natarajan MK, ten Berg JM, Shestakovska O, Gao P, Widimsky P, Džavík V. 2015. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372:1389–98.
1.
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. 2015. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA 313:1113–21.
1.
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. 2015. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv 8:1552–62.
1.
Kholaif N, Zheng Y, Jagasia P, Himmelmann A, James SK, Steg PG, Storey RF, Westerhout CM, Armstrong PW. 2015. Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. Am J Med 128:914.e11–9.
1.
Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, Smahelova A, Hirshberg B, Stahre C, Frederich R, Bonnici F, Scirica BM, Bhatt DL, Raz I. 2015. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 38:1145–53.
1.
Matteau A, Yeh RW, Camenzind E, Steg PG, Wijns W, Mills J, Gershlick A, de Belder M, Ducrocq G, Mauri L. 2015. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol 116:686–93.
1.
Mewton N, Cung TT, Morel O, Cayla G, Bonnefoy-Cudraz E, Rioufol G, Angoulvant D, Guerin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit JF, Jouve B, Motreff P, Tron C, Labeque JN, Steg PG, Cottin Y, Range G, Clerc J, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, Morice MC, Monassier JP, Ider O, Dubois-Randé JL, Unterseeh T, Lebreton H, Beard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Hansson MJ, Elmer E, Boussaha I, Jossan C, Torner A, Claeys M, Garcia-Dorado D, Ovize M. 2015. Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial). Am Heart J 169:758–766.e6.
1.
O’Donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P, Sabatine MS, Morrow DA. 2015. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J 169:622–630.e6.
1.
Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK. 2015. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Eur J Prev Cardiol 22:734–42.
1.
Philippe F, Blin P, Laurendeau C, Bouee S, Gourmelen J, Levy Bachelot L, Leproust S, Steg PG. 2015. Incidence of Cardiovascular Events Following Myocardial Infarction in France: an Observational Analysis Using a Claims Database. Value Health 18:A382.
1.
Potier L, Roussel R, Labreuche J, Marre M, Cacoub P, Röther J, Wilson PW, Goto S, Bhatt DL, Steg PG. 2015. Interaction between diabetes and a high ankle-brachial index on mortality risk. Eur J Prev Cardiol 22:615–21.
1.
Puymirat E, Teixeira N, Simon T, Steg PG, Schiele F, Lamblin N, Probst V, Juillière Y, Ferrières J, Danchin N. 2015. Patient education after acute myocardial infarction: cardiologists should adapt their message–French registry of acute ST-elevation or non-ST-elevation myocardial infarction 2010 registry. J Cardiovasc Med (Hagerstown) 16:761–7.
1.
Sbarouni E, Voudris V, Georgiadou P, Hamilos M, Steg G, Fox KM, Greenlaw N, Vardas PE. 2015. Heart rate and B-blockade in stable coronary artery disease in Greece. Hellenic J Cardiol 56:112–7.
1.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL. 2015. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. Circulation 132:e198.
1.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg G, Bhatt DL. 2015. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial.” Circulation 132:e121–2.
1.
Secemsky EA, Matteau A, Yeh RW, Steg PG, Camenzind E, Wijns W, McFadden E, Mauri L. 2015. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). Am J Cardiol 115:1678–84.
1.
Singh SM, FitzGerald G, Yan AT, Brieger D, Fox KA, López-Sendón J, Yan RT, Eagle KA, Steg PG, Budaj A, Goodman SG. 2015. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. Eur Heart J 36:976–83.
1.
Steg PG, van’t Hof AW, Zeymer U, Goldstein P. 2015. Bivalirudin versus heparin use for patients undergoing PPCI. Lancet 385:2043–4.
1.
Stone GW, Mehran R, Goldstein P, Witzenbichler B, Van’t Hof A, Guagliumi G, Hamm CW, Généreux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG. 2015. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J Am Coll Cardiol 65:27–38.
1.
Stone GW, Mehran R, Steg PG. 2015. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes. JACC Cardiovasc Interv 8:225–7.
1.
Tan NS, Goodman SG, Yan RT, Tan MK, Fox KA, Gore JM, Brieger D, Steg PG, Langer A, Yan AT. 2015. Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. Int J Cardiol 190:34–9.
1.
Terzian Z, Henry-Feugeas MC, Billebeau G, Nejjari M, Ducrocq G, Debray MP, Steg PG, Ou P. 2015. Spectral contrast-enhanced cardiac computed tomography for diagnosis of acute myocarditis. Can J Cardiol 31:691.e9–691.e10.
1.
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. 2015. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 38:696–705.
1.
Van’t Hof A, Giannini F, Ten Berg J, Tolsma R, Clemmensen P, Bernstein D, Coste P, Goldstein P, Zeymer U, Hamm C, Deliargyris E, Steg PG. 2015. ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy. Eur Heart J Acute Cardiovasc Care.
1.
Varenhorst C, Eriksson N, Johansson Å, Barratt BJ, Hagström E, Åkerblom A, Syvänen AC, Becker RC, James SK, Katus HA, Husted S, Steg PG, Siegbahn A, Voora D, Teng R, Storey RF, Wallentin L. 2015. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J 36:1901–12.
1.
White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. 2015. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv 8:424–33.
1.
Wiviott SD, Steg PG. 2015. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet 386:292–302.
1.
Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L. 2015. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol 65:2211–21.

2014

1.
Abtan J, Elbez Y, Bhatt DL, Steg PG. 2014. Lack of negative interaction between use of β-blockers and statins on cardiovascular outcomes among patients with or at risk for atherothrombosis. J Am Coll Cardiol 64:845–7.
1.
Ademi Z, Liew D, Gorelik A, Bohensky M, Zomer E, Hollingsworth B, Steg G, Bhatt DL, Reid CM. 2014. Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data. Int J Cardiol 175:72–7.
1.
Adlbrecht C, Huber K, Reynolds HR, Carvalho AC, Džavík V, Steg PG, Liu L, Marino P, Pearte CA, Rankin JM, White HD, Lamas GA, Hochman JS. 2014. Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. Int J Cardiol 174:90–5.
1.
Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L. 2014. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 35:224–32.
1.
Amarenco P, Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PM, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E. 2014. Impact of living and socioeconomic characteristics on cardiovascular risk in ischemic stroke patients. Int J Stroke 9:1065–72.
1.
Bainey KR, Gafni A, Rao-Melacini P, Tong W, Steg PG, Faxon DP, Lamy A, Granger CB, Yusuf S, Mehta SR. 2014. The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study. J Med Econ 17:415–22.
1.
Balode I, Mintāle I, Latkovskis G, Jēgere S, Narbute I, Bajāre I, Greenlaw N, Steg PG, Ferrari R, Ērglis A. 2014. Insufficient control of heart rate in stable coronary artery disease patients in Latvia. Medicina (Kaunas) 50:295–302.
1.
Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM. 2014. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 7:872–81.
1.
Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. 2014. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 167:437–444.e5.
1.
Camenzind E, Boersma E, Wijns W, Mauri L, Rademaker-Havinga T, Ordoubadi FF, Suttorp MJ, Al Kurdi M, Steg PG. 2014. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. Eur Heart J 35:1932–48.
1.
Cohen A, Assyag P, Boyer-Chatenet L, Cohen-Solal A, Perdrix C, Dalichampt M, Michel PL, Montalescot G, Ravaud P, Steg PG, Boutron I. 2014. An education program for risk factor management after an acute coronary syndrome: a randomized clinical trial. JAMA Intern Med 174:40–8.
1.
Danchin N, Ferrieres J, Guenoun M, Cattan S, Rushton-Smith SK, Greenlaw N, Ferrari R, Steg PG. 2014. Management of outpatients in France with stable coronary artery disease. Findings from the prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) registry. Arch Cardiovasc Dis 107:452–61.
1.
Danchin N, Puymirat E, Steg PG, Goldstein P, Schiele F, Belle L, Cottin Y, Fajadet J, Khalife K, Coste P, Ferrières J, Simon T. 2014. Five-year survival in patients with ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: the French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort. Circulation 129:1629–36.
1.
Ducrocq G, Bhatt DL, Labreuche J, Corbalan R, Porath A, Gao R, Panchenko E, Liau CS, Ikeda Y, Goto S, Amarenco P, Steg PG. 2014. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. Eur J Prev Cardiol 21:1509–16.
1.
Feldman L, Tubach F, Juliard JM, Himbert D, Ducrocq G, Sorbets E, Triantafyllou K, Kerner A, Abergel H, Huisse MG, Roussel R, Esposito-Farèse M, Steg PG, Ajzenberg N. 2014. Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement. Am Heart J 168:940–7.e5.
1.
Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, Coste P, Monsegu J, Gabriel Steg P, Danchin N, Anderson F. 2014. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 4:e004425.
1.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. 2014. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371:1091–9.
1.
Gamra H, Murin J, Chiang CE, Naditch-Brûlé L, Brette S, Steg PG. 2014. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 107:77–87.
1.
Gandhi S, Dorian P, Greenlaw N, Tardif JC, Steg PG, Huynh T, Wong GC, Love MP, Poirier P, Goodman SG. 2014. Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. Can J Cardiol 30:132–7.
1.
Généreux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, Lasalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL. 2014. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 63:619–29.
1.
Halcox JP, Roy C, Tubach F, Banegas JR, Dallongeville J, De Backer G, Guallar E, Sazova O, Medina J, Perk J, Steg PG, Rodríguez-Artalejo F, Borghi C. 2014. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovasc Disord 14:25.
1.
Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA. 2014. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 130:138–46.
1.
Hamon M, Nienaber CA, Galli S, Huber K, Lipiecki J, Hill JM, Amabile N, Bernstein D, Deliargyris E, Lafont A, Steg PG. 2014. Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. Int J Cardiol 173:290–4.
1.
Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG. 2014. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? Am Heart J 168:611–21.
1.
Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M, Himmelmann A, Horrow J, Katus HA, Lassila R, Morais J, Nicolau JC, Steg PG, Storey RF, Wojdyla D, Wallentin L. 2014. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 35:1541–50.
1.
Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. 2014. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 63:2141–7.
1.
Jolly SS, Cairns J, Yusuf S, Meeks B, Shestakovska O, Thabane L, Niemelä K, Steg PG, Bertrand OF, Rao SV, Avezum A, Cantor WJ, Pancholy SB, Moreno R, Gershlick A, Bhindi R, Welsh RC, Cheema AN, Lavi S, Rokoss M, Džavík V. 2014. Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. Am Heart J 167:315–321.e1.
1.
Jolly SS, Cairns J, Yusuf S, Niemela K, Steg PG, Worthley M, Ferrari E, Cantor WJ, Fung A, Valettas N, Rokoss M, Olivecrona GK, Widimsky P, Cheema AN, Gao P, Mehta SR. 2014. Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention. J Am Coll Cardiol 63:954–63.
1.
Kalra PR, García-Moll X, Zamorano J, Kalra PA, Fox KM, Ford I, Ferrari R, Tardif JC, Tendera M, Greenlaw N, Steg PG. 2014. Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients. PLoS ONE 9:e102335.
1.
Kohli P, Steg PG, Cannon CP, Smith SC, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DL. 2014. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med 127:53–60.e1.
1.
Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL. 2014. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 35:2864–72.
1.
Lavallée PC, Labreuche J, Fox KM, Lavados P, Mattle H, Steg PG, Amarenco P. 2014. Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. Neurology 82:1905–13.
1.
Lega JC, Bertoletti L, Gremillet C, Chapelle C, Mismetti P, Cucherat M, Vital-Durand D, Laporte S. 2014. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. PLoS ONE 9:e91398.
1.
Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK. 2014. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 35:2083–93.
1.
Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu CM, Ardissino D, Budaj A, Morais J, Montgomery D, Himmelmann A, Harrington RA, Wallentin L. 2014. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 63:1493–9.
1.
Matteau A, Yeh RW, Kereiakes D, Orav EJ, Massaro J, Steg PG, Normand SL, Cutlip DE, Mauri L. 2014. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol 113:1146–52.
1.
Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. 2014. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–66.
1.
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV. 2014. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 370:1402–11.
1.
Montalescot G, van ’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW. 2014. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–27.
1.
Murin J, Naditch-Brûlé L, Brette S, Chiang CE, O’Neill J, Steg PG. 2014. Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS ONE 9:e86443.
1.
O’Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Steen DL. 2014. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312:1006–15.
1.
Picard FA, Gueret P, Laissy JP, Champagne S, Leclercq F, Carrié D, Juliard JM, Henry P, Niarra R, Chatellier G, Steg PG. 2014. Epicardial adipose tissue thickness correlates with the presence and severity of angiographic coronary artery disease in stable patients with chest pain. PLoS ONE 9:e110005.
1.
Puymirat E, Aissaoui N, Cottin Y, Vanzetto G, Carrié D, Isaaz K, Valy Y, Tchetche D, Schiele F, Steg PG, Simon T, Danchin N. 2014. Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry). Am J Cardiol 114:1651–7.
1.
Puymirat E, Schiele F, Steg PG, Blanchard D, Isorni MA, Silvain J, Goldstein P, Guéret P, Mulak G, Berard L, Bataille V, Cattan S, Ferrières J, Simon T, Danchin N. 2014. Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years. Int J Cardiol 177:281–6.
1.
Ruff CT, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, Hoffman EB, Ohman EM, Eagle KA, Lip GY, Goto S. 2014. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol 170:413–8.
1.
Sbarouni E, Voudris V, Georgiadou P, Hamilos M, Steg PG, Fox KM, Greenlaw N, Ferrari R, Vardas PE. 2014. Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry - results from the Greek national cohort. Hellenic J Cardiol 55:442–7.
1.
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG. 2014. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168:682–9.
1.
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL. 2014. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579–88.
1.
Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F. 2014. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation 130:1139–45.
1.
Sorbets E, Labreuche J, Simon T, Delorme L, Danchin N, Amarenco P, Goto S, Meune C, Eagle KA, Bhatt DL, Steg PG. 2014. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. Eur Heart J 35:1760–8.
1.
Steg PG, Cheong AP. 2014. Death (after percutaneous coronary intervention) is no longer what it used to be. Circulation 129:1267–9.
1.
Steg PG, De Silva R. 2014. Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence? J Am Coll Cardiol 64:253–5.
1.
Steg PG, Greenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, Dorian P, Hu D, Shalnova S, Sokn FJ, Ford I, Fox KM. 2014. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med 174:1651–9.
1.
Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK. 2014. Response to letter regarding article, “Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.” Circulation 129:e494–5.
1.
Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG, Åsenblad N, Wallentin L. 2014. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 25:517–25.
1.
Stępińska J, Marona M, Greenlaw N, Steg G. 2014. Heart rate and the use of beta-blockers in stable outpatients with coronary artery disease: Polish baseline results of the CLARIFY registry. Kardiol Pol 72:1156–64.
1.
Tendera M, Fox K, Ferrari R, Ford I, Greenlaw N, Abergel H, Macarie C, Tardif JC, Vardas P, Zamorano J, Gabriel Steg P. 2014. Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. Int J Cardiol 176:119–24.
1.
Udell JA, Steg PG, Scirica BM, Eagle KA, Ohman EM, Goto S, Alsheikh-Ali AA, Porath A, Corbalan R, Umez-Eronini AA, Hoffman EB, Wilson PW, Bhatt DL. 2014. Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis. Eur J Prev Cardiol 21:1531–40.
1.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HS, Mahaffey KW, Pieper KS, Storey RF, Steg PG, Harrington RA. 2014. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol 170:e59–62.
1.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HA, Mahaffey KM, Pieper KS, Storey RF, Steg PG, Harrington RA. 2014. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol 176:300–2.
1.
Wallentin L, Himmelmann A, Storey RF, Steg PG, Harrington RA. 2014. Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients’ value. Thromb Haemost 112:12–4.
1.
Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JL, Granger CB, Bode C, Huber K, Bates ER, Valgimigli M, Steg PG, Ohman EM. 2014. How can we optimize the processes of care for acute coronary syndromes to improve outcomes? Am Heart J 168:622–31.
1.
Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK. 2014. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 129:293–303.
1.
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. 2014. Response to letter regarding article, “Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.” Circulation 129:e21–2.
1.
Wang KL, Wu CH, Huang CC, Wu TC, Naditch-Brûlé L, Steg PG, Lin SJ, Chiang CE. 2014. Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort. J Cardiol 64:211–7.
1.
Weiss R, Chen H, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. 2014. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370:1702–11.
1.
Welsh RC, Van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, Danays T, Bluhmki E, Lopes RD, Steg PG, Armstrong PW. 2014. Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). Am J Cardiol 114:811–9.
1.
Wijns W, Steg PG, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Lipsic E, Alamgir F, Rademaker-Havinga T, Boersma E, Radke P, van Leeuwen F, Camenzind E. 2014. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. Eur Heart J 35:2812–20.
1.
Zeymer U, van ’t Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, ten Berg J, Coste P, Huber K, Deliargyris EN, Day J, Bernstein D, Goldstein P, Hamm C, Steg PG. 2014. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J 35:2460–7.

2013

1.
Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PG, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Amarenco P. 2013. Demographics, socio-economic characteristics, and risk factor prevalence in patients with non-cardioembolic ischaemic stroke in low- and middle-income countries: the OPTIC registry. Int J Stroke 8 Suppl A100:4–13.
1.
Ademi Z, Huq MM, Liew D, Steg PG, Bhatt DL, Nelson M, Reid CM. 2013. The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry. Cardiovasc Ther 31:370–6.
1.
Ademi Z, Liew D, Hollingsworth B, Steg PG, Bhatt DL, Reid CM. 2013. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort. Cardiovasc Ther 31:45–52.
1.
Ademi Z, Liew D, Zomer E, Gorelik A, Hollingsworth B, Steg PG, Bhatt DL, Reid CM. 2013. Outcomes and excess costs among patients with cardiovascular disease. Heart Lung Circ 22:724–30.
1.
Alonso A, Gore JM, Awad HH, Quill AL, Montalescot G, van de Werf F, Gulba DC, Fox KA, Eagle KA, Granger CB, Wyman A, Steg PG. 2013. Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. Eur Heart J Acute Cardiovasc Care 2:280–91.
1.
Amarenco P, Lavallée PC, Labreuche J, Ducrocq G, Juliard JM, Feldman L, Cabrejo L, Meseguer E, Guidoux C, Adraï V, Ratani S, Kusmierek J, Lapergue B, Klein IF, Gongora-Rivera F, Jaramillo A, Abboud H, Olivot JM, Mazighi M, Touboul PJ, Steg PG. 2013. Coronary artery disease and risk of major vascular events after cerebral infarction. Stroke 44:1505–11.
1.
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F. 2013. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 368:1379–87.
1.
Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Massó-González EL, Sazova O, Perk J, Steg PG, De Backer G, Rodríguez-Artalejo F. 2013. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. Int J Cardiol 166:210–4.
1.
Bangalore S, Steg PG, Bhatt DL. 2013. β-Blocker use for patients with or at risk for coronary artery disease–reply. JAMA 309:439–40.
1.
Barthélémy O, Limbourg T, Collet JP, Beygui F, Silvain J, Bellemain-Appaix A, Cayla G, Chastre T, Baumgartner I, Röther J, Zeymer U, Bhatt DL, Steg G, Montalescot G. 2013. Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. Int J Cardiol 163:266–71.
1.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA. 2013. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368:1303–13.
1.
Bossone E, Corteville DC, Harris KM, Suzuki T, Fattori R, Hutchison S, Ehrlich MP, Pyeritz RE, Steg PG, Greason K, Evangelista A, Kline-Rogers E, Montgomery DG, Isselbacher EM, Nienaber CA, Eagle KA. 2013. Stroke and outcomes in patients with acute type A aortic dissection. Circulation 128:S175–9.
1.
Chiang CE, Goethals M, O’Neill JO, Naditch-Brûlé L, Brette S, Gamra H, Zharinov O, Steg PG. 2013. Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. Europace 15:1733–40.
1.
Ducrocq G, Amarenco P, Labreuche J, Alberts MJ, Mas JL, Ohman EM, Goto S, Lavallée P, Bhatt DL, Steg PG. 2013. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation 127:730–8.
1.
Fassa AA, Wijns W, Kolh P, Steg PG. 2013. Benefit of revascularization for stable ischaemic heart disease: the jury is still out. Eur Heart J 34:1534–8.
1.
Ferrari R, Abergel H, Ford I, Fox KM, Greenlaw N, Steg PG, Hu D, Tendera M, Tardif JC. 2013. Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease. Int J Cardiol 167:2938–43.
1.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. 2013. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J 166:654–661.e6.
1.
Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, Steg PG, Tavazzi L, Tendera M, Ferrari R, Swedberg K. 2013. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 34:2263–70.
1.
Goulenok T, Klein I, Mazighi M, Messika-Zeitoun D, Alexandra JF, Mourvillier B, Laissy JP, Leport C, Iung B, Duval X. 2013. Infective endocarditis with symptomatic cerebral complications: contribution of cerebral magnetic resonance imaging. Cerebrovasc Dis 35:327–36.
1.
Grimaldi-Bensouda L, Rossignol M, Danchin N, Dallongeville J, Bruckert E, Banayan J, Cottin Y, Aubrun E, Khachatryan A, Bénichou J, Abenhaim L. 2013. Real-life effectiveness of statins in the prevention of first acute coronary syndrome in France: a prospective observational study. Int J Cardiol 169:271–5.
1.
Guidoux C, Mazighi M, Lavallée P, Labreuche J, Meseguer E, Cabrejo L, Messika-Zeitoun D, Escoubet B, Touboul PJ, Steg PG, Amarenco P. 2013. Aortic arch atheroma in transient ischemic attack patients. Atherosclerosis 231:124–8.
1.
Hess CN, Schulte PJ, Newby LK, Steg PG, Dalby AJ, Schweiger MJ, Lewis BS, Armstrong PW, Califf RM, van de Werf F, Harrington RA. 2013. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. Eur Heart J Acute Cardiovasc Care 2:246–55.
1.
James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA. 2013. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke 44:1477–9.
1.
James SK, Storey RF, Pieper KS, Cannon CP, Becker RC, Steg PG, Wallentin L, Harrington RA. 2013. Response to letter regarding article, “Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.” Stroke 44:e95–6.
1.
Jolly SS, Cairns J, Niemela K, Steg PG, Natarajan MK, Cheema AN, Rao SV, Cantor WJ, Džavík V, Budaj A, Sheth T, Valentin V, Fung A, Widimsky P, Ferrari E, Gao P, Jedrzejowski B, Mehta SR. 2013. Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial. JACC Cardiovasc Interv 6:258–66.
1.
Juliard JM, Golmard JL, Himbert D, Feldman LJ, Delorme L, Ducrocq G, Descoutures F, Sorbets E, Garbarz E, Boudvillain O, Aubry P, Vahanian A, Steg PG. 2013. Comparison of hospital mortality during ST-segment elevation myocardial infarction in the era of reperfusion therapy in women versus men and in older versus younger patients. Am J Cardiol 111:1708–13.
1.
Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt WR, Goldenberg NA. 2013. Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. J Thromb Haemost 11:1443–8.
1.
Klutstein MW, Westerhout CM, Armstrong PW, Giugliano RP, Lewis BS, Gibson CM, Lutchmedial S, Widimsky P, Steg PG, Dalby A, Zeymer U, Van de Werf F, Harrington RA, Newby LK, Rao SV. 2013. Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. Am Heart J 165:583–590.e1.
1.
Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL. 2013. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 34:1204–14.
1.
Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Hoffman E, Goto S, Ohman EM, Bhatt DL. 2013. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med 126:693–700.e1.
1.
Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM. 2013. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv 6:671–83.
1.
Laissy JP, Gaxotte V, Ironde-Laissy E, Klein I, Ribet A, Bendriss A, Chillon S, Schouman-Claeys E, Steg PG, Serfaty JM. 2013. Cardiac diffusion-weighted MR imaging in recent, subacute, and chronic myocardial infarction: a pilot study. J Magn Reson Imaging 38:1377–87.
1.
Lee D, Goodman SG, Fox KA, DeYoung JP, Lai CC, Bhatt DL, Huynh T, Yan RT, Gallo R, Steg PG, Yan AT. 2013. Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. Am Heart J 166:716–22.
1.
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. 2013. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382:1714–22.
1.
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003.
1.
Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DL. 2013. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 29:417–26.
1.
Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, Sundström J. 2013. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34:1670–80.
1.
Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, Eagle KA, Ohman EM, Umez-Eronini AA, Hoffman E, Bhatt DL. 2013. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol 36:721–7.
1.
Roussel R, Hadjadj S, Pasquet B, Wilson PW, Smith SC, Goto S, Tubach F, Marre M, Porath A, Krempf M, Bhatt DL, Steg PG. 2013. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality. Int J Cardiol 167:1380–4.
1.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. 2013. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–26.
1.
Shal’nova SA, Oganov RG, Steg PG, Ford I. 2013. [Coronary artery disease in Russia: todays reality evidenced by the international CLARIFY registry]. Kardiologiia 53:28–33.
1.
Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S, Lotan C. 2013. Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? Eur Heart J 34:1630–5.
1.
Silva-Cardoso J, Zharinov OJ, Ponikowski P, Naditch-Brûlé L, Lewalter T, Brette S, Steg PG. 2013. Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey. Clin Cardiol 36:766–74.
1.
Sirimarco G, Amarenco P, Labreuche J, Touboul PJ, Alberts M, Goto S, Rother J, Mas JL, Bhatt DL, Steg PG. 2013. Carotid atherosclerosis and risk of subsequent coronary event in outpatients with atherothrombosis. Stroke 44:373–9.
1.
Sirimarco G, Lavallée PC, Labreuche J, Meseguer E, Cabrejo L, Guidoux C, Klein IF, Olivot JM, Abboud H, Adraï V, Kusmierek J, Ratani S, Touboul PJ, Mazighi M, Steg PG, Amarenco P. 2013. Overlap of diseases underlying ischemic stroke: the ASCOD phenotyping. Stroke 44:2427–33.
1.
Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. 2013. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet 382:1879–88.
1.
Steg G. 2013. [Antiplatelet agents]. Bull Acad Natl Med 197:375–87; discussion 387–8.
1.
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA. 2013. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 382:1981–92.
1.
Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK. 2013. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 128:1055–65.
1.
Steg PG, James SK, Gersh BJ. 2013. 2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient management. Heart 99:1156–7.
1.
Steg P, Lopez-de-Sà E, Schiele F, Hamon M, Meinertz T, Goicolea J, Werdan K, Lopez-Sendon JL. 2013. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care 2:270–9.
1.
Steg PG, Mehta SR, Pollack CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim JH, Jeong MH, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS. 2013. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA 310:1145–55.
1.
Steg PG, van ’t Hof A, Clemmensen P, Lapostolle F, Dudek D, Hamon M, Cavallini C, Gordini G, Huber K, Coste P, Thicoipe M, Nibbe L, Steinmetz J, Ten Berg J, Eggink GJ, Zeymer U, Campo dell’ Orto M, Kanic V, Deliargyris EN, Day J, Schuette D, Hamm CW, Goldstein P. 2013. Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention. Am Heart J 166:960–967.e6.
1.
Steg PG, van ’t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell’ Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P. 2013. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 369:2207–17.
1.
Tan NS, Goodman SG, Yan RT, Elbarouni B, Budaj A, Fox KA, Gore JM, Brieger D, López-Sendón J, Langer A, van de Werf F, Steg PG, Yan AT. 2013. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. Am Heart J 166:290–7.
1.
Udell JA, Steg PG, Bhatt DL. 2013. Impact of loneliness and living alone–reply. JAMA Intern Med 173:322–3.
1.
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. 2013. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127:2166–76.

2012

1.
Abola MT, Bhatt DL, Duval S, Cacoub PP, Baumgartner I, Keo H, Creager MA, Brennan DM, Steg PG, Hirsch AT. 2012. Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes. Atherosclerosis 221:527–35.
1.
Ajzenberg N, Ducrocq G, Farnoud R, Huisse MG, Alavoine L, Duval X, Mentré F, Steg PG. 2012. Recurrent acute coronary syndromes are associated with increased shear induced platelet aggregation. A case-control study. Int J Cardiol 155:313–4.
1.
Akerblom Å, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Giannitsis E, Horrow J, Husted S, Katus HA, Steg PG, Storey RF, Åsenblad N, James SK. 2012. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clin Chem 58:190–9.
1.
Amad H, Yan AT, Yan RT, Huynh T, Gore JM, Montalescot G, DeYoung JP, Gallo R, Rose B, Steg PG, Goodman SG. 2012. The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 28:48–53.
1.
Armstrong PW, Siha H, Fu Y, Westerhout CM, Steg PG, James SK, Storey RF, Horrow J, Katus H, Clemmensen P, Harrington RA, Wallentin L. 2012. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation 125:514–21.
1.
Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL. 2012. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308:1340–9.
1.
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ. 2012. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 33:2143–50.
1.
Calvert PA, Steg PG. 2012. Towards evidence-based percutaneous coronary intervention: the René Laënnec lecture in clinical cardiology. Eur Heart J 33:1878–85.
1.
Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O’Neil WW, Jorissen B, Van Leeuwen F, Steg PG. 2012. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 380:1396–405.
1.
Cantú-Brito C, Chiquete E, Ruiz-Sandoval JL, Gaxiola E, Albuquerque DC, Corbalán R, Ramos A, Bhatt DL, Steg PG. 2012. Atherothrombotic disease, traditional risk factors, and 4-year mortality in a Latin American population: the REACH Registry. Clin Cardiol 35:451–7.
1.
Chevreul K, Prigent A, Durand-Zaleski I, Steg PG. 2012. Does lay media ranking of hospitals reflect lower mortality in treating acute myocardial infarction? Arch Cardiovasc Dis 105:489–98.
1.
Chiang CE, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O’Neill J, Silva-Cardoso J, Zharinov O, Gamra H, Alam S, Ponikowski P, Lewalter T, Rosenqvist M, Steg PG. 2012. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 5:632–9.
1.
Cornel JH, Becker RC, Goodman SG, Husted S, Katus H, Santoso A, Steg G, Storey RF, Vintila M, Sun JL, Horrow J, Wallentin L, Harrington R, James S. 2012. Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 164:334–342.e1.
1.
Cueff C, Keenan NG, Krapf L, Steg PG, Cimadevilla C, Ducrocq G, Michel JB, Vahanian A, Messika-Zeitoun D. 2012. Screening for abdominal aortic aneurysm in coronary care unit patients with acute myocardial infarction using portable transthoracic echocardiography. Eur Heart J Cardiovasc Imaging 13:574–8.
1.
Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, Halcox JP, Massó-González EL, Perk J, Sazova O, Steg PG, Artalejo FR. 2012. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol 19:541–50.
1.
Dallongeville J, Bhatt DL, Steg PH, Ravaud P, Wilson PW, Eagle KA, Goto S, Mas JL, Montalescot G. 2012. Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. Eur J Prev Cardiol 19:241–9.
1.
Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O’Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S. 2012. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 11:225–31.
1.
Dimopoulos K, Dudek D, Piscione F, Mielecki W, Savonitto S, Borgia F, Murena E, Manari A, Gaspardone A, Ochala A, Zmudka K, Bolognese L, Steg PG, Flather M, Di Mario C. 2012. Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: implications on optimisation of timing of treatment from the CARESS-in-AMI trial. Int J Cardiol 154:275–81.
1.
Ducrocq G, Bigard MA, Marouene S, Delaage PH, Fabry C, Barthelemy P, Steg PG. 2012. [Risk factors of upper gastrointestinal complications in outpatients on antiplatelet therapy: description and management]. Ann Cardiol Angeiol (Paris) 61:245–51.
1.
Duval S, Massaro JM, Jaff MR, Boden WE, Alberts MJ, Califf RM, Eagle KA, D’Agostino RB, Pedley A, Fonarow GC, Murabito JM, Steg PG, Bhatt DL, Hirsch AT. 2012. An evidence-based score to detect prevalent peripheral artery disease (PAD). Vasc Med 17:342–51.
1.
Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC. 2012. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11:503–11.
1.
Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin L. 2012. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 125:978–86.
1.
Gurm HS, Gore JM, Anderson FA, Wyman A, Fox KA, Steg PG, Eagle KA. 2012. Comparison of acute coronary syndrome in patients receiving versus not receiving chronic dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). Am J Cardiol 109:19–25.
1.
Hamon M, Rao SV, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E. 2012. Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study. EuroIntervention 8:486–92.
1.
Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W. 2012. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11:315–22.
1.
Iung B, Klein I, Mourvillier B, Olivot JM, Détaint D, Longuet P, Ruimy R, Fourchy D, Laurichesse JJ, Laissy JP, Escoubet B, Duval X. 2012. Respective effects of early cerebral and abdominal magnetic resonance imaging on clinical decisions in infective endocarditis. Eur Heart J Cardiovasc Imaging 13:703–10.
1.
Marouene S, Juliard JM, Golmard JL, Aubry P, Ducrocq G, Feldman L, Steg PG, Vahanian A. 2012. [Clinical characteristics, management and prognostic evolution of patients admitted within six hours of symptom onset with st-segment elevation acute myocardial infarction complicated by cardiogenic shock : twenty year monocentric study]. Tunis Med 90:715–9.
1.
Mehran R, Steg PG, White HD, Rao SV. 2012. Letter by Mehran et al regarding article, “Bleeding academic research consortium consensus report: the food and drug administration perspective.” Circulation 125:e460.
1.
Mehta SR, Jolly SS, Cairns J, Niemela K, Rao SV, Cheema AN, Steg PG, Cantor WJ, Džavík V, Budaj A, Rokoss M, Valentin V, Gao P, Yusuf S. 2012. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 60:2490–9.
1.
Moreno JA, Ortega-Gómez A, Delbosc S, Beaufort N, Sorbets E, Louedec L, Esposito-Farèse M, Tubach F, Nicoletti A, Steg PG, Michel JB, Feldman L, Meilhac O. 2012. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. Eur Heart J 33:252–63.
1.
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. 2012. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404–13.
1.
Ohlmann P, Reydel P, Jacquemin L, Adnet F, Wolf O, Bartier JC, Weiss A, Lapostolle F, Gaultier C, Salengro E, Benamer H, Guyon P, Chevalier B, Catan S, Ecollan P, Chouihed T, Angioi M, Zupan M, Bronner F, Bareiss P, Steg G, Montalescot G, Monassier JP, Morel O. 2012. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv 5:69–76, S1.
1.
Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, Khalife K, Goldstein P, Cattan S, Vaur L, Cambou JP, Ferrières J, Danchin N. 2012. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 308:998–1006.
1.
Ranasinghe I, Naoum C, Aliprandi-Costa B, Sindone AP, Steg PG, Elliott J, McGarity B, Lefkovits J, Brieger D. 2012. Management and outcomes following an acute coronary event in patients with chronic heart failure 1999-2007. Eur J Heart Fail 14:464–72.
1.
Reid CM, Ademi Z, Nelson MR, Connor G, Chew DP, Shiel L, Smeath A, De Looze F, Steg PG, Bhatt DL, Liew D. 2012. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust 196:193–7.
1.
Reynolds HR, Forman SA, Tamis-Holland JE, Steg PG, Mark DB, Pearte CA, Carvalho AC, Sopko G, Liu L, Lamas GA, Kruk M, Loboz-Grudzien K, Ruzyllo W, Hochman JS. 2012. Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). Am Heart J 163:462–9.
1.
Schiano P, Steg PG, Barbou F, Monségu J. 2012. A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. Eur Heart J Acute Cardiovasc Care 1:75–8.
1.
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–99.
1.
Smolderen KG, Wang K, de Pouvourville G, Brüggenjürgen B, Röther J, Zeymer U, Parhofer KG, Steg PG, Bhatt DL, Magnuson EA. 2012. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease. Eur J Vasc Endovasc Surg 43:198–207.
1.
Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter T, Merioua I, Murin J, Naditch-Brûlé L, Ponikowski P, Rosenqvist M, Silva-Cardoso J, Zharinov O, Brette S, Neill JO. 2012. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 98:195–201.
1.
Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox KM. 2012. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS ONE 7:e36284.
1.
Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kääb S, Abergel H, Fox KM, Ferrari R. 2012. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J 33:2831–40.
1.
Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van ’t Hof A, Widimsky P, Zahger D. 2012. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–619.
1.
Steg PG, Mehta SR, Pollack CV, Bode C, Gaudin C, Fanouillere K, Moryusef A, Wiviott SD, Sabatine MS. 2012. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J 164:817–24.e13.
1.
Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM. 2012. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307:1817–26.
1.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. 2012. Third universal definition of myocardial infarction. Nat Rev Cardiol 9:620–33.
1.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. 2012. Third universal definition of myocardial infarction. Circulation 126:2020–35.
1.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, others. 2012. Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–98.
1.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. 2012. Third universal definition of myocardial infarction. Eur Heart J 33:2551–67.
1.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW. 2012. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20–33.
1.
Udell JA, Scirica BM, Braunwald E, Raz I, Steg PG, Davidson J, Hirshberg B, Bhatt DL. 2012. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clin Cardiol 35:722–9.
1.
Udell JA, Steg PG, Scirica BM, Smith SC, Ohman EM, Eagle KA, Goto S, Cho JI, Bhatt DL. 2012. Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis. Arch Intern Med 172:1086–95.
1.
Varenhorst C, Alström U, Scirica BM, Hogue CW, Åsenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. 2012. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 60:1623–30.
1.
Venkitachalam L, Wang K, Porath A, Corbalan R, Hirsch AT, Cohen DJ, Smith SC, Ohman EM, Steg PG, Bhatt DL, Magnuson EA. 2012. Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance. Circulation 125:1858–69.
1.
Vergès B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G, Elbaz M, Fredenrich A, Gourdy P, Henry P, Lairez O, Leguerrier AM, Monpère C, Moulin P, Vergès-Patois B, Roussel R, Steg G, Valensi P. 2012. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes Metab 38:113–27.
1.
Vergès B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G, Elbaz M, Fredenrich A, Gourdy P, Henry P, Lairez O, Leguerrier AM, Monpère C, Moulin P, Vergès-Patois B, Roussel R, Steg G, Valensi P. 2012. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Arch Cardiovasc Dis 105:239–53.
1.
White HD, Reynolds HR, Carvalho AC, Pearte CA, Liu L, Martin CE, Knatterud GL, Džavík V, Kruk M, Steg PG, Cantor WJ, Menon V, Lamas GA, Hochman JS. 2012. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. Am Heart J 163:563–71.
1.
Wilson PW, D’Agostino R, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, Dallongeville J, Goto S, Hirsch AT, Liau CS, Ohman EM, Röther J, Reid C, Mas JL, Steg PG. 2012. An international model to predict recurrent cardiovascular disease. Am J Med 125:695–703.e1.

2 thoughts on “Team 5: Atherothrombotic Disease in Heart and Brain

  1. Pingback: Early detection of strokes

  2. Pingback: Stroke: locate, react, restore

Comments are closed.